Celldex announces issuance of patent for CD27 agonists

Celldex Therapeutics announced that the United States Patent and Trademark Office has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27 agonist alone or in combination with other immune modulators" which broadly supports the company's product candidate CDX-1127. CD27, a signaling molecule expressed on T lymphocytes, can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and, due to the restricted expression and regulation of CD27, may result in less toxicity—overcoming a key barrier that other targets in this class have faced. CDX-1127 is a fully human monoclonal antibody that targets CD27 and is currently in Phase 1 clinical development for the treatment of solid tumors and hematologic malignancies.